ArticleVaccines2021

Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial.

Yu-Tzu Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.